Inclusion Criteria:
* 1.Voluntary to participate in the clinical study, sign a written ICF, and able to comply with clinical visits and study-related procedures.
2.Male or female with age ≥18 when signing the ICF. 3.Has a histologically or cytologically confirmed advanced solid tumors who are refractory to or intolerant of available standard-of-care therapy or have no effective standard treatment available.
4.ECOG performance score of 0 or1. 5.Expected survival of at least 3 months. 6.Adequate organ function (without any supportive treatment including blood components, growth factors, etc. within 7 days prior to the laboratory test): Bone marrow: neutrophil count (ANC) ≥ 1.5×109/L, platelet count (PLT) ≥ 90×109/L, and hemoglobin (HGB) \> 9.0 g/dL.
Coagulation function: international normalized ratio (INR) and activated partial prothrombin time (APTT) prolonged to ≤1.5×ULN.
Liver function: total bilirubin (TBIL) ≤ 1.5×ULN or ≤ 3 × ULN in case of known Gilbert disease, alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5×ULN, if there is liver metastasis, ALT or AST ≤ 5×ULN.
Renal function: creatinine clearance ≥ 60 mL/min (using Cockcroft-Gault formula).
Cardiac function: left ventricular ejection fraction (LVEF) ≥ 50%. 7.At least one measurable lesion according to the RECIST v1.1 criteria. 8.Eligible patients with fertility (male and female) must agree to use reliable contraceptive methods (hormonal or barrier method) with their partners during the trial period and at least 3 months after the last administration; female patients of childbearing age must have a negative serum pregnancy test within 7 days before the first dose of YY2201.
Exclusion Criteria:
* 1.Has received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immune checkpoint inhibitor therapy, other anti-tumor treatments, or other un-marketed investigational drugs within 4 weeks prior to first dose of YY2201 (or within 5 half-lives of treatment, whichever is shorter), except for the following items: Have used nitrosourea or Mitomycin C within 6 weeks prior to first dose of Y2201.
Have used oral fluorouracil and small molecule targeted drugs within 2 weeks or 5 half-lives of the drugs prior to first dose of YY2201 (whichever is longer).
Have used herbal therapy with anti-tumor indications are within 2 weeks prior to first dose of YY2201.
2.Has prior (within 2 years before screening) or concurrent other malignancy (except for cured basal cell carcinoma of the skin, carcinoma in situs of cervix, ductal carcinoma in-situ, and prostate cancer which not requiring treatment).
3.Has undergone major organ surgery (excluding biopsy) or have had significant trauma within 4 weeks prior to first dose of YY2201 or required elective surgery during the study period.
4.Is taking (or cannot be stopped at least 1 week prior to first dose of YY2201) any drug that is known to strongly or moderately inhibit or induce CYP2C8 and CYP3A4.
5.The adverse reactions of previous anti-tumor treatments have not yet recovered to grade ≤1 (except for toxicity judged by the investigator to have no safety risk, such as alopecia and fantigue).
6.Has spinal cord compression or brain metastases and requiring corticosteroid therapy at a dose of more than 10 mg prednisone or equivalent per day for at least 4 consecutive weeks prior to initiation of study treatment (unless asymptomatic, treated, and stable) or a history of leptomeningeal metastases.
7.Any gastrointestinal tract related conditions that may affect the drug absorption as judged by the investigator, such as nausea and vomiting that are difficult to control, intestinal obstruction, gastric outlet obstruction, unable to swallow preparations, previous major gastrointestinal resection and so on.
8.Has active infection 1 week before the first dose of YY2201 and currently need systemic anti-infection treatment.
9.HIV infection, or active HBV infection or active HCV infection, with the exception:
1. Patients with serologic evidence of chronic HBV infection and have HBV viral load below the limit of quantification with normal liver function.
2. Patients with serologic evidence of HCV infection and have negative hepatitis C virus RNA test results.
10.History of serious cardiovascular and cerebrovascular diseases, including but not limited to: Severe cardiac rhythm or conduction abnormality, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrioventricular block, etc., PR interval \> 250 ms; Thromboembolic events requiring therapeutic anticoagulation, or subjects with a venous filter; Patients with Class III\~IV cardiac insufficiency according to the criteria of New York Heart Association (NYHA); Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other grade 3 or higher cardiovascular and cerebrovascular events within 12 months prior to the first dose; QT interval corrected through Fridericia's formula (QTcF) prolongation (male \> 450 ms, female \> 470 ms); any factors that increase the risk of QTc prolongation and arrhythmia, such as heart failure, congenital long QT syndrome, family history of long QT syndrome, and QT interval prolongation caused by any concomitant drug.
11.History of non-infectious pneumonitis (NIP)/pneumonitis requiring systemic steroids, or active NIP/ pneumonitis, or other severe lung disease.
12.Substance use disorder that may interfere with the participant's involvement in the study or evaluation of the study result, as determined by the investigator.
13.Patient with mental disorders, severe cognitive disorder, poor compliance, or is not suitable for participating in this clinical study determined by the Investigator.
14.Women who are pregnant or breastfeeding. 15.Patient who cannot tolerate venous blood sampling. 16.Known allergy to YY2201 or any of its excipient. 17.History of other serious systemic diseases, or not suitable to participate in this study for other reasons as judged by the Investigator.
